June 2009 News@MSKCC

An MSKCC researcher has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.

MSKCC has now made keeping track of details regarding care easier by creating a private, personalized online link for patients to access this information and communicate with their physicians and nurses.

MSKCC experts report that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer.

New research led by investigators at MSKCC identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs.

Findings from a new study led by researchers at MSKCC show that while laparoscopic surgeries generally took longer to perform than open procedures, the minimally invasive approach yielded shorter hospital stays, a decreased need for postoperative pain relief, fewer complications after surgery, and similar rates of recurrence-free survival.

A new multi-center study shows that an experimental drug lowers PSA levels in men with advanced prostate cancer for whom traditional treatment options have failed.

Researchers at MSKCC have gained new insight into how circulating tumor cells can help predict the prognosis of patients with castration-resistant prostate cancer.

MSKCC medical oncologist Katharine C. Hsu and colleagues have described an immune benefit of allogeneic, or donor-provided, blood stem cell transplants in patients being treated for leukemia.

Research conducted at MSKCC's Geoffrey Beene Translational Oncology Core Facility helps increase our understanding of the genes involved in cancer.

Researchers at MSKCC are exploring whether a new generation of nanoparticles called "C dots" can assist in tumor detection and treatment.

Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan-Kettering Institute, has been named the recipient of two prestigious awards.

The American Association for Cancer Research recently awarded Charles L. Sawyers, Chair of MSKCC's Human Oncology and Pathogenesis Program, the 2009 Dorothy P. Landon Prize for Translational Cancer Research.

MSKCC physician-scientist David A. Scheinberg was recently elected a member of the Association of American Physicians.